Last reviewed · How we verify

Golytely 4 liters

Temple University · FDA-approved active Small molecule Quality 2/100

Golytely 4 liters is a Small molecule drug developed by Temple University. It is currently FDA-approved. Also known as: polyethylene glycol/electrolytes.

Golytely 4 liters, marketed by Temple University, is a bowel preparation solution with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use in bowel preparation. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameGolytely 4 liters
Also known aspolyethylene glycol/electrolytes
SponsorTemple University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Golytely 4 liters

What is Golytely 4 liters?

Golytely 4 liters is a Small molecule drug developed by Temple University.

Who makes Golytely 4 liters?

Golytely 4 liters is developed and marketed by Temple University (see full Temple University pipeline at /company/temple-university).

Is Golytely 4 liters also known as anything else?

Golytely 4 liters is also known as polyethylene glycol/electrolytes.

What development phase is Golytely 4 liters in?

Golytely 4 liters is FDA-approved (marketed).

Related